{"entity":{"id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","aka":[],"tldr":"A phase 3 trial of carboplatin and lurbinectedin in lung cancer, run by Zai Lab (Shanghai) Co., Ltd., not yet recruiting.","summary":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07796100 by Zai Lab (Shanghai) Co., Ltd., with a registry enrolment figure of 530 participants, started 2026-12-31 and due to reach its primary completion in 2030-06-30. Interventions recorded: ZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance. Conditions listed: Extensive-Stage Small Cell Lung Cancer. Primary outcome: Overall survival of ZL-1310 with IO compared to chemo with IO. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed ES-SCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07796100","url":"https://clinicaltrials.gov/study/NCT07796100"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","lurbinectedin"],"companies":["zai-lab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07796100","phase":"3","setting":"A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer","sponsor":"Zai Lab (Shanghai) Co., Ltd.","enrolled":530,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07796100/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"}],"company":[{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}